View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 2, 2021

Aurinia reports positive results from trial of lupus nephritis treatment

Phase III AURORA 2 clinical trial has assessed the tolerability and safety of Lupkynis to treat LN in patients with SLE.

Aurinia Pharmaceuticals has reported positive interim results from the AURORA 2 continuation study of Lupkynis (voclosporin) to treat lupus nephritis (LN).

The structurally modified calcineurin inhibitor (CNI) Lupkynis is intended to treat adult patients with LN, which is a serious manifestation of systemic lupus erythematosus (SLE).

The randomised, double-blind, placebo-controlled Phase III AURORA 2 clinical trial is evaluating the tolerability and safety of the oral medicine to treat LN in patients with SLE, a complex chronic autoimmune disease.

Participants who have completed a one-year treatment during the Phase III AURORA 1 trial were eligible for enrolment in the AURORA 2 continuation study.

In this study, the LN patients were given 23.7mg voclosporin or placebo in combination with 1g mycophenolate mofetil twice a day for 24 additional months.

According to the interim analysis, around 216 patients continued into the AURORA 2 study and received total treatment for 30 months.

It was observed that the patients in the LN group who received Lupkynis sustained meaningful reductions in proteinuria with a stable estimated glomerular filtration rate (eGFR) at 30 months.

Furthermore, lupkynis showed sustained safety and tolerability compared to placebo.

Aurinia Pharmaceuticals chief medical officer Neil Solomons said: “We are encouraged to see the continued positive outcomes with Lupkynis and look forward to seeing and presenting the complete results from AURORA 2 in the coming months.”

The final results of the AURORA 2 continuation study are anticipated to be released by the end of this year.

In May 2021, Aurinia reported positive results from a Phase III AURORA 1 study of oral therapy Lupkynis in adult patients with LN.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena